Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCejuela, Mónica-
dc.contributor.authorMartin Castillo, Begoña-
dc.contributor.authorMenendez, Javier A.-
dc.contributor.authorPernas, Sonia-
dc.description.abstractBreast cancer is the most prevalent cancer and the leading cause of cancer-related death among women worldwide. Type 2 diabetes-associated metabolic traits such as hyperglycemia, hyperinsulinemia, inflammation, oxidative stress, and obesity are well-known risk factors for breast cancer. The insulin sensitizer metformin, one of the most prescribed oral antidiabetic drugs, has been suggested to function as an antitumoral agent, based on epidemiological and retrospective clinical data as well as preclinical studies showing an antiproliferative effect in cultured breast cancer cells and animal models. These benefits provided a strong rationale to study the effects of metformin in routine clinical care of breast cancer patients. However, the initial enthusiasm was tempered after disappointing results in randomized controlled trials, particularly in the metastatic setting. Here, we revisit the current state of the art of metformin mechanisms of action, critically review past and current metformin-based clinical trials, and briefly discuss future perspectives on how to incorporate metformin into the oncologist's armamentarium for the prevention and treatment of breast cancer.-
dc.format.extent19 p.-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofInternational Journal of Molecular Sciences, 2022, vol. 23, num. 5-
dc.rightscc by (c) Cejuela, Mónica et al, 2022-
dc.subject.classificationCàncer de mama-
dc.subject.otherBreast cancer-
dc.titleMetformin and Breast Cancer: Where Are We Now?-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
ijms-23-02705-v3.pdf1.5 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons